Cardiovascular mortality among chronic myeloid leukemia patients in the pre-tyrosine kinase inhibitor (TKI) and TKI eras: a surveillance, epidemiology and end results (SEER) analysis-Reference-Cited by-同舟云学术

Cardiovascular mortality among chronic myeloid leukemia patients in the pre-tyrosine kinase inhibitor (TKI) and TKI eras: a surveillance, epidemiology and end results (SEER) analysis

Published:2020-01-27 Issue:5 Volume:61 Page:1147-1157
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Wang Qian¹²^ORCID,Jiang Changchuan²,Zhang Yaning³,Zhang Yu⁴,Yue Bing²,Zheng-Lin Binbin²,Zhao Yang⁵,Mauro Michael J.⁶

Affiliation:

1. Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA;

2. Department of Medicine, Icahn School of Medicine at Mount Sinai St. Luke's and Mount Sinai West, New York, NY, USA;

3. Department of General Surgery, Cleveland Clinic, Cleveland, OH, USA;

4. Department of Hematology, Chinese People's Liberation Army Hospital 307, Beijing, China;

5. Division of Cardiology, Lanzhou University Second Hospital, Lanzhou, China;

6. Myeloproliferative Neoplasms Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2019.1711074

Reference73 articles.

1. An observational study on risk of secondary cancers in chronic myeloid leukemia patients in the TKI era in the United States

2. Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios

3. Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV

4. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials

5. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group [see comments]

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Incidence rate and risk factors for suicide in patients with breast cancer in the USA: A surveillance, epidemiology, and end results analysis (SEER);European Journal of Oncology Nursing;2024-08

2. Competing risk analysis of cardiovascular death in breast cancer: evidence from the SEER database;Translational Cancer Research;2023-12

3. Risk of chronic liver disease and cirrhosis mortality among patients with digestive system cancers: a registry-based analysis;Clinical and Experimental Medicine;2023-10-03

4. Cardiovascular Mortality among Patients with Pancreatic Cancer: A Population-based Study;2023-06-26

5. A practical guide to managing cardiopulmonary toxicities of tyrosine kinase inhibitors in chronic myeloid leukemia;Frontiers in Medicine;2023-05-05